GLUE vs VRTX vs BEAM vs CRL vs MEDP

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Vertex Pharmaceuticals Incorporated (VRTX) offers the better valuation at 29. 0x trailing P/E (23. 1x forward), making it the more compelling value choice. Analysts rate Monte Rosa Therapeutics, Inc. (GLUE) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Vertex Pharmaceuticals Incorporated (VRTX) is the cheapest at 29.

0x versus Medpace Holdings, Inc. at 31. 1x. On forward P/E, Charles River Laboratories International, Inc. is actually cheaper at 16. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Medpace Holdings, Inc. wins at 0. 88x versus Vertex Pharmaceuticals Incorporated's 2. 78x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +171. 2%, compared to -66. 9% for Beam Therapeutics Inc. (BEAM). Over 10 years, the gap is even starker: MEDP returned +1582% versus GLUE's -13. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vertex Pharmaceuticals Incorporated (VRTX) is the lower-risk stock at 0.

68β versus Beam Therapeutics Inc. 's 2. 18β — meaning BEAM is approximately 219% more volatile than VRTX relative to the S&P 500. On balance sheet safety, Monte Rosa Therapeutics, Inc. (GLUE) carries a lower debt/equity ratio of 17% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Vertex Pharmaceuticals Incorporated grew EPS 836. 5% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.

7% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps 32. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39. 4% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — GLUE leads at 93. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Medpace Holdings, Inc. (MEDP) is the more undervalued stock at a PEG of 0. 88x versus Vertex Pharmaceuticals Incorporated's 2. 78x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Charles River Laboratories International, Inc. (CRL) trades at 16. 9x forward P/E versus 28. 0x for Medpace Holdings, Inc. — 11. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GLUE: 85. 7% to $31. 75.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +1582% 10Y return). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MEDP: +1582%, BEAM: +54. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GLUE is a small-cap high-growth stock; VRTX is a mid-cap quality compounder stock; BEAM is a small-cap high-growth stock; CRL is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.